Skip to content
A6628Assembly2021-2022 Session

Notify on Psych Med Changes

Official title

“Relates to designating an individual to be notified in the case of dose or brand change for psychotropic medication”

Sponsor William A. BarclayAD-120+7 co-sponsorsAffects Health
Status
In Assembly Committee
Health
Impact
4/10
Low
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill allows patients to designate someone to be notified and give written consent before any change to their psychotropic medication.

Why it matters

  1. Empowers patients by allowing them to involve a trusted individual in critical medication decisions, potentially increasing advocacy and oversight for vulnerable populations, especially those who may struggle to self-advocate due to cognitive or mental health challenges.

  2. Mandates written notification and informed consent (including acknowledgment of specific rights in the case of gradual dose reductions), which could reduce the risk of adverse drug reactions, withdrawal effects, and unwanted changes in mental health treatment by ensuring someone reviews proposed medication changes.

  3. Requires that notifications include detailed warnings about possible side effects and drug interactions, addressing a common gap in patient safety and aiming to minimize harm due to incomplete communication about medication risks.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Notify on Psych Med Changes

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Held for consideration in health
  2. Referred to health
  3. Referred to health

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

6628

2021-2022 Regular Sessions

IN ASSEMBLY

March 23, 2021

Introduced by M. of A. BARCLAY, MANKTELOW, SALKA, LEMONDES, DeSTEFANO, M. MILLER, J. M. GIGLIO, BLANKENBUSH -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to designating an individual to be notified in the case of dose or brand change for psychotropic medication

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 3 of section 2803-c of the public health law is amended by adding a new paragraph s to read as follows:

s. (i) Pursuant to regulations promulgated by the commissioner, every patient shall have the right to designate an individual to be notified in the event that the facility reduces the dose or changes the brand or form of the patient's psychotropic medication. Such notification shall include a warning listing possible side effects and drug interactions, including side effects upon discontinuation of such drugs. Notification shall be made in writing, and shall not be effective until receipt of the written consent of the designated individual. In the case of a gradual dose reduction, a designee shall check a box acknowledging such designee has been given a copy of the rights pertaining to gradual dose reductions.

(ii) For the purposes of this paragraph, "psychotropic medication" means a medication that is administered for the purpose of affecting brain activities associated with mental processes and behavior, including, but not limited to, anti-psychotics, anti-depressants, anxiolytics, sedatives and hypnotics.

§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD03002-02-1

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.